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Since hyperinsulinaemia may promote obesity-linked cancers, we compared type 2 diabetes prevalence among oesophageal
adenocarcinoma (OAC) patients and population controls. Diabetes increased the risk of OAC (adjusted odds ratio 1.59, 95% confidence
interval (CI) 1.04–2.43), although the risk was attenuated after further adjusting for body mass index (1.32, 95% CI 0.85–2.05).
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Adenocarcinomas of the oesophagus (OAC) and gastro-oesopha-
geal junction (GOJAC) have been rising rapidly in incidence in
many countries (Blot et al, 1991; Wayman et al, 2001; Pohl and
Welch, 2005), widely attributed to the steadily rising prevalence of
obesity (Silventoinen et al, 2004; Reeves et al, 2007; Whiteman
et al, 2007; Corley et al, 2008).
One proposed mechanism to explain the association between
obesity and OAC is that obesity increases the risk of OAC through
the pathway of gastro-oesophageal acid reflux. However, we and
others have shown that obesity is strongly associated with OAC
(Corley et al, 2008) even among people with no history of reflux
(Chow et al, 1998; Whiteman et al, 2007), arguing against
increased exposure to acid as being the sole mechanism for the
observed phenomenon. A second postulated mechanism is that the
metabolic changes accompanying adiposity establish a hormonal
milieu that promotes the development of nascent tumours (Calle
and Kaaks, 2004).
A candidate hormone central to the ‘metabolic hormonal
hypothesis’ is insulin. Insulin activates the insulin receptor,
triggering intracellular signalling cascades with mitogenic and
antiapoptotic effects (Calle and Kaaks, 2004). In addition, its
positive feedback influences levels of leptin, a mitogenic adipo-
cytokine that has been implicated in cancers of the colon, breast
and prostate (Tessitore et al, 2000; Stattin et al, 2003). If
hyperinsulinaemia is positively associated with the risk of OAC,
then an association with type 2 diabetes (a proxy for pre-existing
hyperinsulinaemia) should be observed, independently of other
obesity-related factors.
Although some studies investigated oesophageal cancer in
relation to diabetes, only three distinguished adenocarcinomas
from squamous cell carcinomas (Cheng et al, 2000; Reavis et al,
2004; Rubenstein et al, 2005). For each study, however, the
prevalence of diabetes among controls was markedly different
from prevailing population estimates. We therefore used data from
a large population-based case–control study to explore the
hypothesis and address some gaps in the evidence.
METHODS
The study was approved by the human research ethics committees
of the Queensland Institute of Medical Research and participating
hospitals and we obtained written informed consent from all
participants. Details of recruitment and data collection have been
reported earlier (Whiteman et al, 2007). Briefly, patients (cases)
with a primary invasive OAC or oesophageal squamous cell
carcinoma (OSCC) or diagnosed between 1 July 2001 and 30 June
2005 were recruited through major treatment centres and state-
based cancer registries throughout mainland Australia. In all, 1102
patients returned questionnaires (75% of those meeting the
inclusion criteria and invited to take part: 367 OAC, 426 GOJAC
and 309 OSCC).
Potential controls were randomly selected from the Australian
electoral roll (enrolment is compulsory), matched to the distribu-
tion of the case-series by age, sex and state of residence. Completed
questionnaires were returned by 1580 controls (52% of all controls
meeting the inclusion criteria).
Data were collected through self-completed questionnaires
about education, occupation, smoking, medication use, maximum
weight and height and weight 1 year ago. We calculated BMI by
dividing weight in kilograms by the square of height in metres.
Participants were asked about the frequency of symptoms of
gastro-oesophageal reflux. For analysis, we defined ‘frequent
symptoms’ as those occurring at least weekly.
Diabetes was self-reported using the questions ‘Have you ever
had diabetes treated with insulin injections?’ and ‘Have you ever
had diabetes treated with tablets and/or diet?’ A positive response
to either of these questions prompted a question about the age of
diagnosis. We classified those who reported diabetes treated only
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ywith tablets/diet as having type 2 diabetes. Participants who had
insulin-treated diabetes were considered to have type 2 diabetes if
they were diagnosed after the age of 25 years.
Details of the histological type and anatomical site of each
tumour were abstracted from diagnostic pathology reports.
Tumours were categorised according to the WHO classification
as ‘oesophageal’ or of the ‘gastro-oesophageal junction’ (Spechler
et al, 2000). We calculated the odds ratios (ORs) and 95%
confidence intervals (95% CIs) associated with diabetes using
multivariable logistic regression analysis in SAS version 9.1 (SAS
Institute Inc., Cary, NC). We first fitted models that contained
terms for diabetes, age and sex (Model 1). We then estimated risks
associated with diabetes adjusted for these variables and educa-
tion, smoking, frequency of aspirin use and frequency of gastro-
oesophageal reflux symptoms (Model 2). Finally, we fitted models
comprising the preceding variables as well as BMI (Model 3).
RESULTS
The demographic and clinical characteristics of cases and controls
have been reported earlier (Sadeghi et al, 2008). Diabetes was self-
reported by 7% of controls, compared with 14, 12 and 4% of cases
who had OAC, GOJAC and OSCC, respectively.
In simple models adjusted only for age and sex, we found a
significant increase in the risk of OAC associated with diabetes
(Model 1: OR 1.78, 95% CI 1.22–2.62) that was somewhat
attenuated by adjustment for additional factors (Table 1). Adding
the term for BMI to the model further attenuated the estimate, with
the final OR suggesting a 32% increase in risk of OAC associated
with diabetes, although this increase was no longer statistically
significant (Model 3: OR 1.32, 95% CI 0.85–2.05). Similar patterns
were observed for GOJAC, although the magnitude of association
was smaller. There was some suggestion that people whose
diabetes had been diagnosed greater than 10 years before their
adenocarcinoma had a greater risk than those whose onset of
diabetes was more recent (Table 1).
We observed consistently higher risks of OAC among those with
diabetes within each category of BMI. People with diabetes who
were also obese were at a 3.5-fold higher risk of OAC than those
with neither risk factor (OR 3.55, 95% CI 1.87–6.76). Oesophageal
adenocarcinoma risks were somewhat lower in those with either
obesity or diabetes alone (obese OR 2.67, 95% CI 1.80–3.96;
diabetes OR 1.86, 95% CI 0.65–5.31). In contrast to OAC, the odds
of OSCC were significantly lower in people with diabetes compared
with those without (OR 0.54, 95% CI 0.29–1.0) (Table 1).
DISCUSSION
Obesity is an established risk factor for OAC, although the precise
mechanism involved remains unknown. An emerging hypothesis is
that metabolic aberrations accompanying obesity lead to changes
in hormones and cytokines, including insulin. We indirectly tested
this ‘metabolic hormonal hypothesis’ by comparing the diabetes
prevalence among oesophageal cancer patients with population
controls, and found that those with adenocarcinoma were more
likely than controls to report a history of diabetes. The association
was greater for long-standing diabetes than for more recent
diagnoses. In contrast, we found the suggestion of an inverse
association between diabetes and OSCC.
The risk estimates generated by different multivariable models
warrant comment. As excess body fat leads to high levels of insulin
(and eventually to diabetes) and as diabetes is a proxy measure for
hyperinsulinaemia, the inclusion of terms for both of these factors
in the same model may underestimate the real effect of
hyperinsulinaemia. One could argue that the effect of hyperinsu-
linaemia is best estimated by Model 2, which adjusts the
association between diabetes and OAC for factors that might
explain the confounding effect of BMI (e.g., gastro-oesophageal
Table 1 Relative risks for adenocarcinomas of the oesophagus (OAC), gastro-oesophageal junction (GOJAC) and squamous cell carcinoma (OSCC)
associated with type 2 diabetes; minimally, partially and fully adjusted for confounding factors
History of type 2 diabetes Control (N) Case (N) OR (95% CI)
a OR (95% CI)
b OR (95% CI)
c
OAC
No diabetes 1423 293 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 46 1.78 (1.22–2.62) 1.59 (1.04–2.43) 1.32 (0.85–2.05)
No diabetes 1423 293 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes duration o10 years 68 25 1.46 (0.90–2.38) 1.39 (0.82–2.36) 1.14 (0.66–1.97)
Diabetes duration X10 years) 30 18 2.45 (1.32–4.57) 1.96 (0.97–3.97) 1.65 (0.80–3.40)
P-trend 0.18
GOJAC
No diabetes 1423 338 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 44 1.56 (1.06–2.28) 1.44 (0.96–2.16) 1.23 (0.82–1.87)
No diabetes 1423 338 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes (duration o10 years) 68 20 1.06 (0.63–1.79) 0.90 (0.57–1.71) 0.87 (0.50–1.51)
Diabetes (duration X10 years) 30 22 2.76 (1.55–4.91) 2.46 (1.33–4.55) 2.16 (1.16–4.04)
P-trend 0.07
OSCC
No diabetes 1423 270 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 12 0.54 (0.29–1.0) 0.48 (0.25–0.91) 0.57 (0.30–1.10)
No diabetes 1423 270 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes (duration o10 years) 68 7 0.49 (0.22–1.08) 0.42 (0.18–0.97) 0.52 (0.23–1.20)
Diabetes (duration X10 years) 30 5 0.73 (0.28–1.92) 0.62 (0.23–1.67) 0.70 (0.25–1.93)
P-trend 0.17
CI¼confidence interval; OR¼odds ratio.
aOR: Model 1: adjusted for age (in years) and sex.
bOR: Model 2: adjusted for age (in years), education level, cumulative smoking
history, frequency of gastro-oesophageal reflux symptoms 10 years before diagnosis and frequency of aspirin use in the last 5 years.
cOR: Model 3: as for Model 2 with an
additional term for BMI.
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yreflux), but without overadjusting the association with hyperinsu-
linaemia (Rothman, 2002).
To address potential selection bias in controls, we compared the
age-specific prevalence of diabetes in our control group with that
reported in the population-based Australian Diabetes Survey
(Dunstan et al, 2001) and found a very high concordance. Patients
may have lost weight before their diagnosis, so we performed all
analyses using maximum reported BMI, with negligible difference
in the results.
We found only three earlier studies that investigated the
association between diabetes and OAC (Cheng et al, 2000; Reavis
et al, 2004; Rubenstein et al, 2005). Of these, one found a
substantial and significant increase in risk of OAC with diabetes
(Reavis et al, 2004), one reported an OR of close to one
(Rubenstein et al, 2005) and the third a highly unstable risk
estimate of 7.00 (95% CI 0.85–56.89) (Cheng et al, 2000). In all
three studies, the prevalence of diabetes among controls was
different from population estimates, raising concerns about
generalisability.
In summary, our data support the hypothesis that diabetes is
associated with an increased risk of OAC and that this is unlikely
to be due entirely to other factors associated with a high BMI.
Resolution of this question requires a further analysis of existing
or new population-based data sets, in which histological subtypes
are treated as separate entities.
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